BioSpace News Archive

IRLAB Therapeutics announced that the company will present at the Redeye Life Science Day 2023 on Thursday, November 23, 2023, in Stockholm, Sweden.

Sobi® will present new data at the 65th Annual Meeting of the American Society of Hematology in San Diego from the 9th to the 12th of December 2023.

BioNxt Solutions Inc. is pleased to provide further details on its clinical and commercialization strategy for its recently announced 100% Cladribine IP acquisition and related clinical programs.

Astex Pharmaceuticals announced that it is in line to receive a milestone payment from AstraZeneca on first commercial sale of the drug in the US and royalties from AstraZeneca on future sales following the US Food and Drug Administration’s approval of Truqap™ plus Faslodex® as a treatment for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations.

RaySearch Laboratories AB announces that University Hospital of Southern Denmark in Vejle, Denmark has developed a new and groundbreaking workflow for adapting a patient’s treatment plan during the first treatment session.

Enterome today announced updated efficacy data from its Phase 1/2 clinical trial of EO2401, in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab), for the treatment of patients with first progression/recurrence of glioblastoma (ROSALIE trial).

TeDan Surgical Innovations, a leading player in the medical technology sector, is thrilled to announce its inclusion in the Halma Group.

Tryp Therapeutics Inc. is pleased to announce that it has closed its previously announced private placement of unsecured convertible notesfor aggregate gross proceeds of AUD$3,215,000 which represents an oversubscription of AUD$215,000 above its previously announced minimum placement of AUD$3,000,000.

NeoImmuneTech, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for their investigational drug NT-I7 (efineptakin alfa) (rhIL-7-hyFc) for the treatment of Acute Radiation Syndrome (ARS).

Fosun Pharma USA and Treehill Partners (Treehill) announce the formation of a jointly operating vehicle for investment in clinical stage assets, further solidifying the relationship between the two companies.